HomeCompareIPCIF vs PEP

IPCIF vs PEP: Dividend Comparison 2026

IPCIF yields 1333.33% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPCIF wins by $241528700.47M in total portfolio value
10 years
IPCIF
IPCIF
● Live price
1333.33%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$241528700.61M
Annual income
$210,475,860,072,406.56
Full IPCIF calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — IPCIF vs PEP

📍 IPCIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPCIFPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPCIF + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPCIF pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPCIF
Annual income on $10K today (after 15% tax)
$113,333.33/yr
After 10yr DRIP, annual income (after tax)
$178,904,481,061,545.56/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, IPCIF beats the other by $178,904,481,008,951.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPCIF + PEP for your $10,000?

IPCIF: 50%PEP: 50%
100% PEP50/50100% IPCIF
Portfolio after 10yr
$120764350.38M
Annual income
$105,237,930,067,141.12/yr
Blended yield
87.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

IPCIF
No analyst data
Altman Z
-111.3
Piotroski
4/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPCIF buys
0
PEP buys
0
No recent congressional trades found for IPCIF or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPCIFPEP
Forward yield1333.33%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$241528700.61M$141.9K
Annual income after 10y$210,475,860,072,406.56$61,875.67
Total dividends collected$239239876.27M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: IPCIF vs PEP ($10,000, DRIP)

YearIPCIF PortfolioIPCIF Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$144,033$133,333.33$10,849$509.42+$133.2KIPCIF
2$1,948,924$1,794,807.89$11,969$750.47+$1.94MIPCIF
3$24,782,219$22,696,870.86$13,500$1,124.14+$24.77MIPCIF
4$296,245,945$269,728,970.81$15,680$1,721.66+$296.23MIPCIF
5$3,330,378,004$3,013,394,842.54$18,929$2,715.34+$3330.36MIPCIF
6$35,223,684,321$31,660,179,856.69$24,023$4,450.80+$35223.66MIPCIF
7$350,636,384,108$312,947,041,885.16$32,510$7,669.92+$350636.35MIPCIF
8$3,286,630,500,315$2,911,449,569,318.85$47,709$14,093.60+$3286630.45MIPCIF
9$29,021,346,295,663$25,504,651,660,325.88$77,415$28,083.48+$29021346.22MIPCIF
10$241,528,700,608,766$210,475,860,072,406.56$141,922$61,875.67+$241528700.47MIPCIF

IPCIF vs PEP: Complete Analysis 2026

IPCIFStock

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Full IPCIF Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this IPCIF vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPCIF vs SCHDIPCIF vs JEPIIPCIF vs OIPCIF vs KOIPCIF vs MAINIPCIF vs MOIPCIF vs PMIPCIF vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.